Last reviewed · How we verify
Placebo (GA-0034)
Placebo (GA-0034) is an inert control substance with no active pharmacological mechanism.
At a glance
| Generic name | Placebo (GA-0034) |
|---|---|
| Sponsor | GW Pharmaceuticals Ltd |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, GA-0034 contains no active pharmaceutical ingredient and produces no direct molecular or biological effect. It is used as a control comparator in clinical trials to assess the efficacy and safety of investigational drugs by isolating the true pharmacological effects from placebo response.
Approved indications
Common side effects
Key clinical trials
- A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS) (PHASE3)
- Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer (PHASE3)
- A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer (PHASE3)
- Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer (PHASE3)
- Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis. (PHASE3)
- Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (GA-0034) CI brief — competitive landscape report
- Placebo (GA-0034) updates RSS · CI watch RSS
- GW Pharmaceuticals Ltd portfolio CI